Managing HIV has never been more convenient. For individuals who are already virally suppressed on oral antiretroviral therapy (ART), long-acting injectable treatment using cabotegravir and rilpivirine offers a new way to maintain control—without daily pills.
If you live in New Jersey and are looking for a discreet, low-maintenance HIV treatment plan, injectable options may be right for you.
What Is Long-Acting HIV Treatment?
Long-acting HIV treatment uses a combination of two injectable medications—cabotegravir, an integrase strand transfer inhibitor (INSTI), and rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI). These medications are delivered via intramuscular injection, typically once a month or every two months, depending on your treatment plan.
This approach maintains viral suppression without the need for daily pills.
Who Is Eligible?
Long-acting treatment is currently approved for people who:
- Are 18 years or older
- Have an undetectable viral load
- Have no history of resistance to cabotegravir or rilpivirine
- Do not have hepatitis B (or are otherwise appropriately managed)
- Can consistently attend clinic appointments for injections
Before starting injections, most patients complete a short lead-in phase with oral versions of both drugs to ensure they tolerate them well.
Benefits of Long-Acting Injectables
Many patients prefer injectable HIV treatment for the freedom and privacy it offers.
Key advantages include:
- No daily medication reminders
- Increased privacy—no pill bottles
- Reduced chance of missed doses
- Less stigma from others seeing medications
- Maintained viral suppression with fewer treatment days per year
This is an ideal option for people who travel, face challenges with daily adherence, or simply want more flexibility in their HIV care.
What to Expect During Treatments
- Initial visits include labs, medical evaluation, and possibly a 30-day oral lead-in.
- Injections are administered at a healthcare facility, typically in the gluteal muscle.
- Your provider will monitor your viral load and side effects regularly.
- You’ll need to attend each appointment on schedule, as missing an injection can impact your viral suppression.
Long-acting treatment is safe, effective, and a great option for people who are engaged in routine HIV care and want a simpler approach.
Staying on Track Is Key
While the dosing schedule is less frequent, long-acting HIV treatment still requires commitment. Missing injections by more than a few days could lead to a drop in medication levels and increase the risk of resistance.
It’s important to:
- Keep scheduled visits
- Communicate with your care team if you’re running late or traveling
- Discuss any side effects or life changes that could impact your treatment plan
Ready to Learn if Long-Acting HIV Treatment Is Right for You?
If you’re currently undetectable and want to explore more convenient treatment options, long-acting injectables may be a great fit. Whether you’re seeking privacy, travel flexibility, or help with medication adherence, this option offers a powerful new tool for long-term HIV management.
We’ll help you:
Take the first step toward a healthier future today.
🔹 Treatment Duration: 12 weeks
🔹 Cure Rate: 98%
🔹 Approved for all six Hep C genotypes
🔹 Works for patients with or without cirrhosis
Why choose Epclusa? This medication is a great option for many people, especially those with different strains of Hep C or mild to moderate liver disease.
🔹 Treatment Duration: 8 weeks (shortest treatment for most people!)
🔹 Cure Rate: 97-100%
🔹 Works for all six Hep C genotypes
🔹 Safe for patients with mild to severe liver disease
Why choose Mavyret? This is one of the fastest Hepatitis C treatments available, making it ideal for people who want a shorter treatment period.
🔹 Treatment Duration: 8-12 weeks
🔹 Cure Rate: 95-99%
🔹 Most effective for genotypes 1, 4, 5, and 6
🔹 Can be used in some children (age 3 and older)
Why choose Harvoni? This medication is especially beneficial for patients with Hep C genotype 1 and has a long history of success in curing Hepatitis C.